Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.43 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19586956 | 1.00 | IDO1 (0.50) | IDO1ITGAVITGB6CTSSCTSK | |
| SCHEMBL19586958 | 1.00 | IDO1 (0.50) | IDO1ITGAVITGB6CTSSCTSK | |
| SCHEMBL23782050 | 0.93 | IDO1 (0.52) | IDO1CTSSCTSKCTSL | |
| SCHEMBL27231152 | 0.93 | IDO1 (0.52) | IDO1CTSSCTSKCTSL | |
| SCHEMBL23782048 | 0.93 | IDO1 (0.52) | IDO1CTSSCTSKCTSL | |
| SCHEMBL8278579 | 0.93 | IDO1 (0.52) | IDO1CTSSCTSKCTSL | |
| SCHEMBL23824418 | 0.92 | IDO1 (0.44) | IDO1CTSSCTSK | |
| SCHEMBL23824420 | 0.92 | IDO1 (0.44) | IDO1CTSSCTSK | |
| SCHEMBL29063292 | 0.92 | IDO1 (0.44) | IDO1CTSSCTSK | |
| SCHEMBL29062824 | 0.92 | CTSS (0.52) | IDO1CTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118159548-A | Antiviral compounds | 安力高医药股份有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-11987554-B2 | Protease inhibitors as antivirals | VIVASOR, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-09 | — | — | US | disclosed |
| EP-4352040-A1 | PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| EP-4347034-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11952365-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | EMORY UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | disclosed |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-01-13 | — | — | US | disclosed |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | EMORY UNIVERSITY (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210395300-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | UNIV EMORY (US) | 2021-12-23 | — | — | US | disclosed |
| WO-2021252491-A1 | ANTI-VIRAL COMPOUNDS FOR TREATING CORONAVIRUS, PICORNAVIRUS, AND NOROVIRUS INFECTIONS | ALIGOS THERAPEUTICS, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | EMORY UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY | 2021-01-14 | — | — | US | disclosed |
| WO-2020247665-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3455205-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | Emory University (US) | 2019-03-20 | — | — | EP | disclosed |
| WO-2017197377-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | EMORY UNIVERSITY (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021513-B2 | Peptidomimetics for the treatment of norovirus infection | VIP, HAVCR2, NGLY1 | IDO1 2265/4885ITGAV 1175/4885ITGB6 3435/4885 |
| US-11952365-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | IDO1 3030/4885ITGAV 2888/4885ITGB6 3991/4885 |
| US-11859014-B2 | Peptidomimetics for the treatment of Norovirus infection | VIP, HAVCR2, NGLY1 | IDO1 2265/4885ITGAV 1175/4885ITGB6 3435/4885 |
| US-20210008150-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS | ACE2, SARS1, VIP | IDO1 967/4885ITGAV 2423/4885ITGB6 4433/4885 |
| US-11851422-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | IDO1 3030/4885ITGAV 2888/4885ITGB6 3991/4885 |
| US-11987554-B2 | Protease inhibitors as antivirals | ACE, ACE2, TMPRSS15 | IDO1 996/4885ITGAV 3730/4885ITGB6 4675/4885 |
| US-20220009903-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | IDO1 3030/4885ITGAV 2888/4885ITGB6 3991/4885 |
| US-20200071354-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | IDO1 2265/4885ITGAV 1175/4885ITGB6 3435/4885 |
| US-11207370-B2 | Peptidomimetics for the treatment of coronavirus and picornavirus infections | ACE2, SARS1, VIP | IDO1 967/4885ITGAV 2423/4885ITGB6 4433/4885 |
| US-20210395300-A1 | PEPTIDOMIMETICS FOR THE TREATMENT OF NOROVIRUS INFECTION | VIP, HAVCR2, NGLY1 | IDO1 2265/4885ITGAV 1175/4885ITGB6 3435/4885 |
| US-20240150318-A1 | PROTEASE INHIBITORS FOR TREATMENT OF CORONAVIRUS INFECTIONS | ACE, ACE2, TMPRSS2 | IDO1 1238/4885ITGAV 3846/4885ITGB6 3257/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | IDO1 3030/4885ITGAV 2888/4885ITGB6 3991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.